212 related articles for article (PubMed ID: 26868508)
21. Novel therapies to increase apolipoprotein AI and HDL for the treatment of atherosclerosis.
Wong NC
Curr Opin Investig Drugs; 2007 Sep; 8(9):718-28. PubMed ID: 17729183
[TBL] [Abstract][Full Text] [Related]
22. ApoA-I mimetics.
Stoekenbroek RM; Stroes ES; Hovingh GK
Handb Exp Pharmacol; 2015; 224():631-48. PubMed ID: 25523005
[TBL] [Abstract][Full Text] [Related]
23. The Effect of Bromodomain and Extra-Terminal Inhibitor Apabetalone on Attenuated Coronary Atherosclerotic Plaque: Insights from the ASSURE Trial.
Shishikura D; Kataoka Y; Honda S; Takata K; Kim SW; Andrews J; Psaltis PJ; Sweeney M; Kulikowski E; Johansson J; Wong NCW; Nicholls SJ
Am J Cardiovasc Drugs; 2019 Feb; 19(1):49-57. PubMed ID: 30155718
[TBL] [Abstract][Full Text] [Related]
24. Inducing apolipoprotein A-I synthesis to reduce cardiovascular risk: from ASSERT to SUSTAIN and beyond.
Di Bartolo BA; Scherer DJ; Nicholls SJ
Arch Med Sci; 2016 Dec; 12(6):1302-1307. PubMed ID: 27904522
[TBL] [Abstract][Full Text] [Related]
25. Recombinant high-density lipoprotein formulations.
Vucic E; Rosenson RS
Curr Atheroscler Rep; 2011 Feb; 13(1):81-7. PubMed ID: 21057986
[TBL] [Abstract][Full Text] [Related]
26. An experimental study on amelioration of dyslipidemia-induced atherosclesis by Clematichinenoside through regulating Peroxisome proliferator-activated receptor-α mediated apolipoprotein A-I, A-II and C-III.
Liu C; Guo Q; Lu M; Li Y
Eur J Pharmacol; 2015 Aug; 761():362-74. PubMed ID: 25979856
[TBL] [Abstract][Full Text] [Related]
27. HDL-cholesterol: is it really good? Differences between apoA-I and HDL.
Santos-Gallego CG; Ibanez B; Badimon JJ
Biochem Pharmacol; 2008 Aug; 76(4):443-52. PubMed ID: 18547543
[TBL] [Abstract][Full Text] [Related]
28. Compositional Features of HDL Particles Interact with Albuminuria to Modulate Cardiovascular Disease Risk.
Corsetti JP; Bakker SJL; Gansevoort RT; Gruppen EG; Connelly MA; Sparks CE; Dullaart RPF
Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30813431
[TBL] [Abstract][Full Text] [Related]
29. RVX-208, an inducer of Apolipoprotein A-I, inhibits the particle production of hepatitis B virus through activation of cGAS-STING pathway.
Shu D; Cheng L; Yuan K; Liu D; Wei H
Antivir Ther; 2023 Dec; 28(6):13596535231219639. PubMed ID: 38037795
[TBL] [Abstract][Full Text] [Related]
30. BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes.
Wasiak S; Dzobo KE; Rakai BD; Kaiser Y; Versloot M; Bahjat M; Stotz SC; Fu L; Sweeney M; Johansson JO; Wong NCW; Stroes ESG; Kroon J; Kulikowski E
Clin Epigenetics; 2020 Nov; 12(1):166. PubMed ID: 33172487
[TBL] [Abstract][Full Text] [Related]
31. Hepatocyte-specific ABCA1 transfer increases HDL cholesterol but impairs HDL function and accelerates atherosclerosis.
Feng Y; Lievens J; Jacobs F; Hoekstra M; Van Craeyveld E; Gordts SC; Snoeys J; De Geest B
Cardiovasc Res; 2010 Nov; 88(2):376-85. PubMed ID: 20562425
[TBL] [Abstract][Full Text] [Related]
32. Genome-wide screen for modulation of hepatic apolipoprotein A-I (ApoA-I) secretion.
Miles RR; Perry W; Haas JV; Mosior MK; N'Cho M; Wang JW; Yu P; Calley J; Yue Y; Carter Q; Han B; Foxworthy P; Kowala MC; Ryan TP; Solenberg PJ; Michael LF
J Biol Chem; 2013 Mar; 288(9):6386-96. PubMed ID: 23322769
[TBL] [Abstract][Full Text] [Related]
33. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice.
van der Hoorn JW; de Haan W; Berbée JF; Havekes LM; Jukema JW; Rensen PC; Princen HM
Arterioscler Thromb Vasc Biol; 2008 Nov; 28(11):2016-22. PubMed ID: 18669886
[TBL] [Abstract][Full Text] [Related]
34. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.
Fruchart JC; Duriez P
Drugs Today (Barc); 2006 Jan; 42(1):39-64. PubMed ID: 16511610
[TBL] [Abstract][Full Text] [Related]
35. The rationale for using apoA-I as a clinical marker of cardiovascular risk.
Barter PJ; Rye KA
J Intern Med; 2006 May; 259(5):447-54. PubMed ID: 16629850
[TBL] [Abstract][Full Text] [Related]
36. Relation of high-density lipoprotein cholesterol:apolipoprotein a-I ratio to progression of coronary atherosclerosis in statin-treated patients.
Mani P; Uno K; St John J; Tuzcu EM; Nissen SE; Nicholls SJ
Am J Cardiol; 2014 Sep; 114(5):681-5. PubMed ID: 25030535
[TBL] [Abstract][Full Text] [Related]
37. RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain.
Picaud S; Wells C; Felletar I; Brotherton D; Martin S; Savitsky P; Diez-Dacal B; Philpott M; Bountra C; Lingard H; Fedorov O; Müller S; Brennan PE; Knapp S; Filippakopoulos P
Proc Natl Acad Sci U S A; 2013 Dec; 110(49):19754-9. PubMed ID: 24248379
[TBL] [Abstract][Full Text] [Related]
38. Common variation in cholesteryl ester transfer protein: relationship of first major adverse cardiovascular events with the apolipoprotein B/apolipoprotein A-I ratio and the total cholesterol/high-density lipoprotein cholesterol ratio.
Kappelle PJ; Gansevoort RT; Hillege HJ; Wolffenbuttel BH; Dullaart RP;
J Clin Lipidol; 2013; 7(1):56-64. PubMed ID: 23351584
[TBL] [Abstract][Full Text] [Related]
39. Different relationship between ANGPTL3 and HDL components in female non-diabetic subjects and type-2 diabetic patients.
Zhao D; Yang LY; Wang XH; Yuan SS; Yu CG; Wang ZW; Lang JN; Feng YM
Cardiovasc Diabetol; 2016 Sep; 15(1):132. PubMed ID: 27620179
[TBL] [Abstract][Full Text] [Related]
40. Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial.
Tricoci P; D'Andrea DM; Gurbel PA; Yao Z; Cuchel M; Winston B; Schott R; Weiss R; Blazing MA; Cannon L; Bailey A; Angiolillo DJ; Gille A; Shear CL; Wright SD; Alexander JH
J Am Heart Assoc; 2015 Aug; 4(8):e002171. PubMed ID: 26307570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
